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Abstract
Background: The current guidelines for treatment of malaria include paracetamol to children with fever. No
convincing evidence for the beneficial effects of this practice exists. Studies show that time to parasite clearance is
significantly longer in children treated with paracetamol, which questions the policy. Whether this is of clinical
importance has not been investigated.
Methods: Children with Plasmodium falciparum monoinfection and ≥20 parasites per 200 leucocytes at the
Bandim Health Centre, Guinea-Bissau were randomized to receive paracetamol or placebo together with
chloroquine for three days in a double blind randomized study. Temperature and symptoms were recorded twice
daily during treatment and on day 3. The participants were interviewed and a malaria film taken once weekly until
day 35. The data is in the form of grouped failure-times, the outcome of interest being time until parasitaemia
during follow-up. Mantel-Haenszel weighted odds ratios are given. Other differences between and within the two
groups have been tested using the Chi-square test and Mann-Whitney U test.
Results: In the evening of the day of inclusion, the temperature was slightly, but statistically insignificant, higher in
the placebo group and significantly more children complained of headache. At no other time was a significant
difference in temperature or symptoms detected. However, 6 children from the placebo-group as compared to
two children from the paracetamol-group were admitted to hospital with high fever and convulsions by day 3. No
differences in the cumulative percentages of children with adequate clinical and parasitological response were
found in the intention-to-treat analysis or in the per-protocol analysis.
Conclusion: Fewer children had early treatment failure and the mean temperature was slightly lower in the
afternoon on day 0 in the paracetamol group. However, the cumulative adequate clinical and parasitological cure
rates were not significantly different during the period of study. It is doubtful whether adding paracetamol to the
treatment of uncomplicated malaria in children is beneficial.
Trial registration: NCT00137566.
Background
Fever is a common symptom of many childhood illnesses.
Although the disease process may be harmful, there is no
evidence that fever is harmful in itself. In fact, fever may
be beneficial by enhancing the host response to infection
[1,2]. There are few prospective human studies on
whether antipyretics have any clinically relevant effects.
According to a Cochrane Review, evidence that paraceta-
mol has a superior antipyretic effect compared with
placebo is inconclusive [3]. Still, many parents and physi-
cians believe that antipyretic treatment improves the
comfort of febrile children and antipyretics are therefore
commonly prescribed. Although paracetamol is generally
regarded as a safe antipyretic drug, liver failure is a well-
known consequence of paracetamol overdose [4,5] and
multiple doses of paracetamol, only marginally greater
than the recommended maximum dose, might cause * Correspondence: pekofoed@dadlnet.dk
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any medium, provided the original work is properly cited.liver damage [6], especially in febrile and acutely mal-
nourished children [7].
T h er o l eo ff e v e ri nm a l a r i ai su n c l e a r .T u m o u rn e c r o -
sis factor (TNF) is an important mediator of fever in
malaria [8,9], and experimental data suggest that both
TNF and fever have anti-parasitic properties [10,11]. In a
small study, Krishna et al found a longer parasite clear-
ance time when paracetamol was used [12]. This finding
was confirmed by a study in Gabon in which children
with non-severe P. falciparum malaria were randomized
to receive mechanical antipyretics (continuous fanning,
tepid sponging and cool blankets) either alone or in com-
bination with paracetamol [13]. Time to parasitic clear-
ance was significantly longer and the level of TNF
reduced in the paracetamol group suggesting that the
longer parasite clearance time could be due to decreased
production of TNF and oxygen radicals [13].
The current WHO guidelines on the management of
fever recommend the use of paracetamol for children with
a temperature of 38.5°C or above [14] and the National
Malaria Programme in Guinea-Bissau recommends para-
cetamol for all children treated for malaria. Still, the costs
are not negligible and the adverse events can be serious
[4-7,15]. It is therefore important to evaluate if treatment




The study was performed in the area of Bandim on the
outskirts of Bissau, Guinea-Bissau. Parents from Bandim
attending the Bandim Health Centre with children weight-
ing more than 7.5 kg and having fever or other symptoms
compatible with malaria and stating that the children had
not taken any antimalarial drug during the previous week
were informed of the study. Included children had a thick
film examined for malaria. Children with convulsions,
severe vomiting, severe anaemia, a severe concurrent
infection or who for other reasons were considered in
need of hospital care were not eligible.
Children with mono-infection with P. falciparum and 20
or more parasites per 200 leukocytes (= 800/μl assuming a
leukocyte count of 8000/μl) were enrolled from June 2004
to July 2006. Children were allocated to one of six 5 kg-
interval weight groups or to a group of children with a
body-weight above 37.5 kg. For each weight group, num-
bered boxes had been prepareda tr a n d o mw i t he i t h e rp a r a -
cetamol tablets or undistinguishable placebo tablets
corresponding to approximately 50 mg paracetamol per kg
bodyweight per day for three days. The children were given
study numbers consecutively within each weight-group.
The first dose of paracetamol/placebo from the tablet-box
corresponding to the study number of the child was given
by an experienced nurse at the health centre. For logistic
reasons (home-visits could not be performed at intervals
matching the intervals between medications) the mothers
were then given the tablet-box containing tablets until the
end of day 2 and were carefully instructed on how to give
the tablets. A health worker visited the house on day 3 and
asked to see the tablet-box and counted the number of
remaining tablets. The randomisation numbers were kept
separately at the Department of Paediatrics in Kolding,
Denmark. An interim analysis was made by one of the
researchers not involved in the recruitment of the patients
when a total of 40 and 140 children had completed the fol-
low-up to ensure that none of the groups had an unaccep-
table high rate of recurrent parasitaemia using the results of
previous in-vivo chloroquine studies as guidelines [16-18].
Following recommendations of the National Malaria
Programme at the time of the study, 25 mg/kg body-
weight of chloroquine was split into daily doses of 10,
10 and 5 mg/kg and given days 0, 1 and 2 for treatment
of malaria. An experienced nurse ascertained that the
tablets were swallowed and recorded the time the dose
was given. If the child did not turn up as planned, a
project health worker went to the house to ensure the
medication. If the child vomited within 30 minutes after
receiving the tablets, the dose was repeated. If the child
vomited again during the next 30 minutes, a dose of
10 mg Quinimax
® dihydrochloride (Sanofi Winthrop,
Gentilly, France) per kg bodyweight was given intramus-
cularly and the child was referred to hospital.
Tablets with 160 mg chloroquine-phosphate (= 100
mg chloroquine base) were obtained from Recip SB,
12054 Årsta, Sweden. Paracetamol tablets of 500 mg
and undistinguishable placebo tablets were obtained
from GlaxoSmithKline, Dungarvan, Irland.
The children or their mothers were asked for any
symptoms twice daily on day 0, day 1 and day 2 and in
the evening on day 3. At the same time, the axillary tem-
perature was measured using an electronic thermometer.
Follow-up
Following treatment, the children were visited once weekly
until day 35 for thick and thin films. The mothers were
interviewed about any medication given since the last visit,
and the health worker assessed the condition of the child.
During the study period, the parents were asked to bring
the child to the health centre in case of any illness to
ensure early detection of clinical malaria. All treatments
were free during the study-period. Recrudescent infections
were treated according to the national recommendations
which were then sulphadoxine/pyrimethamine or, for
severe cases, quinine.
Microscopy
Before inclusion, a thick and a thin film were examined.
Thick films were also examined on day 3, 7, 14, 21, 28
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child sought medical attention at the Bandim Health
Centre due to fever or other symptoms suggestive of
malaria. To ensure the quality of the microscopy, 10%
of the thick films were re-examined by an experienced
laboratory technician. The parasites were counted per
200 leukocytes. If abundant, the number of leukocytes
was counted per 500 parasites.
Polymerase chain reaction
Each time a thick smear was made, approximately 100 μL
of blood was also put onto filter paper, dried and then
stored in a separate sealed plastic bag. Approximately
50 μl of blood was cut from the filter papers and DNA
was extracted using an ABI Prism 6100 Nucleic Acid
Prep Station (Applied Biosystems, Fresno, CA) according
to the manufacturer’s recommendations. Extracted DNA
was frozen at -20°C until amplification by PCR. Mero-
zoite surface protein 1 (pfmsp1)a n dm e r o z o i t es u r f a c e
protein 2 (pfmsp2) were amplified by PCR as described
previously [19]. PCR products were separated on agarose
g e l s( A m r e s c o ,S o l o n ,O H ) ,s tained with ethidium bro-
mide and visualised under UV trans-illumination (BioRad
GelDoc System, BioRad, Hercules, CA). Pfmsp1 and
pfmsp2 were amplified from DNA collected on the day of
inclusion and the day of failure. Recrudescent infections
were defined as reappearance of at least one band from
both pfmsp1 and pfmsp2 during the follow-up or the re-
appearance of a band in the successfully amplified gene if
either pfmsp1 or 2 failed. Re-infections were defined as
those where no band re-occurred. Whenever a child
received antimalarial medication elsewhere, the blood
sample drawn on the last visit was analysed.
Outcome measures
Early treatment failure (ETF) was defined as 1) develop-
ment of severe malaria or appearance of danger signs on
day 1 to 3; 2) positive malaria film and temperature ≥
37.5°C on day 3; or 3) parasitaemia on day 3 ≥ 25% of the
parasitaemia on day 0. Late clinical failure (LCF) was
defined as either; 1) fever and a positive malaria film; 2) a
history of fever and clinical symptoms of malaria as well as
a positive malaria film. Late parasitological failure (LPF)
was defined as reappearing parasiteamia on day 7 or later
for children without ETF or LCF. Adequate clinical and
parasitological response (ACPR) was defined as absence of
parasitaemia without the child meeting any of the criteria
of ETF, LCF or LPF.
T h ep r i m a r yo u t c o m ew a st h ec u m u l a t i v eP C R - u n c o r -
rected ACPR rate until day 35 and PCR-corrected failure
rates on day 28 and 35. Secondary outcomes were the
ETF rates, the symptoms as reported by the mothers, the
temperature measured during the treatment with
paracetamol/placebo; and possible clinical adverse effects
of the medication given.
Statistical analysis
An intention-to-treat analysis was performed to answer
the question as to whether the treatments were valuable
for the children [20,21]. Therefore, all children admitted
to hospital on the day of inclusion were considered as
ETF, and all children treated by a third person with an
anti-malarial during follow-up were considered as LCF.
Children who could not be found during medication or
the first follow-up visit due to unknown addresses were
considered to have violated the entry criteria of living in
Bandim and were therefore excluded.
A per protocol analysis was done to evaluate the effi-
cacy of the treatments. Children admitted to hospital on
the day of inclusion were then excluded as they were
considered to be so sick that they had been included in
violation of the inclusion criteria. Children treated out-
side the study during follow up without having re-para-
sitaemia confirmed by a positive malaria film and/or a
positive PCR-analysis were considered withdrawal of
consent and excluded on the day of retreatment.
The data is in the form of grouped failure-times, the
outcome of interest being time until parasitaemia during
follow-up. Mantel-Haenszel weighted odds ratios are
given. Loss to follow-up between two analysis times has
been treated by censoring at the beginning of the time
interval. Other differences between and within the two
groups have been tested using the Chi-square test and
Mann-Whitney U test.
Ethics
The protocol stated that any study group should be ter-
minated if parasitaemia reappeared in 50% or more of at
least 40 children. Ethical clearance was obtained from
Direcção de Higiene e Epidemiologia, Ministério da
Saúde Publica in Guinea-Bissau (030/DHE/2004) and
the Central Ethical Committee in Denmark (2004-7041-
11). Children and/or their parents were informed of the
study orally as the literacy rate is low. Written informa-
tion in Creole was given on request. The information
was standardised and in accordance with the principles
of the Helsinki declaration. This trial was registered at
ClinicalTrials.gov [22] with the study ID: PSB-2004-
paracetamol (NCT00137566).
Results
A total of 14.861 children were screened at the Bandim
Health Centre and 3.569 had a malaria film examined
due to symptoms compatible with malaria. Of these, 354
had 20 or more parasites per 200 leucocytes. Six chil-
dren were not included as they were leaving the study
Kofoed et al. Malaria Journal 2011, 10:148
http://www.malariajournal.com/content/10/1/148
Page 3 of 8area and 5 were not included for unknown reasons. Five
children or their caretakers refused to participate. The
remaining 338 children who fulfilled the inclusion cri-
teria were randomised into one of the two study groups.
The number of children lost to follow-up and the num-
ber of children with reappearing parasitaemia are shown
in Figure 1. There were no differences in sex, age, body-
weight, dose of chloroquine received per kg body-weight
or parasite density on inclusion between the two groups
(Table 1).
In the paracetamol and the placebo groups 59% (99/
167) and 59% (100/170) of the children, respectively
claimed to have taken paracetamol during the past 12
hours prior to inclusion. During the three days of treat-
ment, only 1 (0.3%), 14 (4.1%) and 17 (5.0%) children
received paracetamol or other anti-pyretic apart from
w h a th a db e e np r e s c r i b e do ni n c l u s i o n .O nd a y3 ,a f t e r
ending the treatment prescribed at the health centre, a
total of 34 children (10.1%) were given paracetamol.
There were no differences between the two study groups
on any of the days.
When asked to show the tablet-box on day 3, 39%
(62/161) and 37% (60/161) in the paracetamol and the
placebo groups respectively, still had tablets left with a
median number of 1.5 (range 0.5 - 6.0) vs. 2.0 (range:
0.5 - 6.0). The rest showed empty boxes. Assuming that
the children had taken the tablets removed from the
boxes, the median dose during the 3 days were 136 mg
paracetamol/kg (range: 0 - 188) and 143 mg placebo/kg
(range: 0 - 188), respectively (p = 0.34).
On inclusion, there were no differences between the
g r o u p si nt h es y m p t o m sa n ds i g n sr e p o r t e db yt h e
mothers. The most frequent symptoms and signs were
that the child felt/looked ill (99%, 334/338), had fever
(87%, 295/338), had eaten less (84%, 285/338), had head-
ache (83%, 279/338), vomited (41%, 138/338), had diar-
rhoea (14%. 49/338), and drank less (7%, 22/338). In the
evening of day 0, more children in the placebo group
complained of headache than in the paracetamol group
(105/164 vs. 86/165, p = 0.03). For all other complaints,
no statistical significant differences were found during
the first three days (data not shown). On day one, three
children in the paracetamol group and eight children in
the placebo group complained of itching (p = 0.13), but
continued the anti malarial treatment. Due to vomiting,
11 children in the paracetamol group and two children
in the placebo group had the first dose of chloroquine
repeated. The second dose was repeated in four and
three children respectively. On day 3, parasites were
detected in 19 and 21 of the children in the paracetamol
and the placebo group, respectively (OR: 0.88 (95% con-
fidence interval: 0.43 - 1.79)).
The temperature was measured in the morning and
evening of day 0, day 1 and day 2 and in the evening on
day 3 (Table 2). In the evening of day 0, the temperature
was higher in the placebo group than in the paracetamol
group (p = 0.01), however when applying the Bonferro-
ni’s correction for multiple comparisons this finding was
n o ts t a t i s t i c a l l ys i g n i f i c a n t( ps h o u l db el e s st h a n0 . 0 0 7
for detecting a statistically s i g n i f i c a n td i f f e r e n c ea tt h e
5% level). The six children admitted to hospital due to
high fever and convulsions during the three days of
treatment had a median temperature of 38.5°C on inclu-
sion (37.4°C - 39.9°C) as compared to 37.6°C (36.7°C -
38.9°C) for the children not admitted to hospital during
the treatment (p = 0.27).
One child from the paracetamol group was admitted
to hospital on each of the days 2 and 3. From the pla-
cebo group, 3, 2 and 1 children were admitted on day 0,
day 1, and day 3, respectively. All were admitted due to
high fever and convulsions (2/167 vs. 6/171. OR: 0.33
(0.03 - 1.90)). Two children in the paracetamol group
were admitted to hospital after the end of the treatment,
one at day 7 and one at day 14, both due to high fever.
One child in the placebo group was admitted at day 5
due to anaemia.
A total of 72 children had paired blood-samples from
day 0 and the day of reappearing parasitaemia analysed.
Filter-paper-samples from six children with LPF or LCF
were not available on the day of reparasitaemia, includ-
ing samples from three children admitted to hospital
after end of treatment and 2 treated outside the study.
Pfmsp 1 and 2 amplification failed in 11 samples col-
lected on the day of treatment failure, three of these
were treated outside the study. No differences in the
cumulative percentages of children with ACPR were
found, in the intention-to-treat analysis or in the per-
protocol analysis (Tables 3 and 4).
There were 25 and 16 PCR adjusted LPF + LCF in the
paracetamol and placebo groups respectively (OR: 1.55
(0.78 - 3.16)) (Table 5). When added to the 2 and 7
ETF a total of 27 and 23 treatment failures were found
(OR: 1.16 (0.63 - 2.15)) (Table 5). The cumulative OR of
having ETF or PCR adjusted LPF or LCF on day 7 or
before vs. after day 7 was 0.49 (0.18 - 1.24) and 2.72
(1.07 - 7.77), respectively.
Discussion
Common to other febrile diseases, children suffering
from clinical malaria are mostly treated with paraceta-
mol in addition to an anti-malarial drug. Some animal
studies have shown that fever increases survival during
infection whilst antipyreticsi n c r e a s em o r t a l i t y[ 2 3 - 2 6 ] .
As parasites exposed to paracetamol were less likely to
be eliminated, concerns about the routine use of parace-
tamol have been raised [12,13].
In the present study we compared the outcome when
children with uncomplicated m a l a r i aw e r et r e a t e dw i t h
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Page 4 of 8Screened using thick smear 3569 
Not included: 16. Of these: 
Leaving the study area: 6 
refused to participate: 5 
unknown reason: 5.  
Fulfilling inclusion 
criteria: 354 
Outcome day 3 
Unknown address: 1 
ACPR: 164 and ETF: 2 
Outcome day 28 
Lost to follow-up: 2 
ACPR: 111 and LPF/LCF: 5 
Outcome day 7 
Lost to follow-up: 3                             
ACPR: 152 and LPF/LCF*: 9 
Placebo group:  
Enrolled: 171 
 
Outcome day 14 
Lost to follow-up: 5 
ACPR: 133 and LPF/LCF**: 14 
Outcome day 21 
Lost to follow-up: 7 
ACPR: 115 and LPF/LCF: 11 
Outcome day 3 
Unknown adress: 3                             
ACPR: 161 and ETF: 7 
Outcome day 28 
Lost to follow-up: 2 
ACPR: 108 and LPF/LCF: 5 
Outcome day 7 
Lost to follow-up: 0                             
ACPR: 147 and LPF/LCF*: 14 
Outcome day 14 
Lost to follow-up: 3 
ACPR: 131 and LPF/LCF: 13 
Outcome day 35 
Lost to follow-up: 10 
ACPR: 97 and LPF/LCF: 1 
Outcome day 21 
Lost to follow-up: 6 
ACPR: 118 and LPF/LCF: 7 
Paracetamol group:  
Enrolled: 167 
Outcome day 35 
Lost to follow-up: 7 
ACPR: 102 and LPF/LCF: 2 
Figure 1 The reasons for lost to follow-up were mainly due to the children travelling outside the study-area (20 and 16 in
paracetamol and placebo groups, respectively). One child in the paracetamol group withdrew consent on day 14 and for one child in each
of the study groups no information could be obtained. Due to the staff being involved in the national vaccination campaign 2 children were
lost to follow-up on day 28 and 3 on day 35. LPF/LCF: including children treated outside the study. *: Including one child from each of the
groups admitted to hospital. **: Including one child in the paracetamol group admitted to hospital.
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Page 5 of 8chloroquine, the anti-malarial recommended by the
National Malaria Control Programme in Guinea-Bissau
at the time, plus either placebo or paracetamol. The fact
that parents consider paracetamol important was con-
firmed as approximately 60% of the children had
received paracetamol prior to inclusion and that most of
the paracetamol/placebo prescribed was taken during
the 3 days of treatment.
Almost all children suffered from symptoms generally
believed to be alleviated by paracetamol like feeling ill,
eating less, and having a headache. In the afternoon on
the day of inclusion, a higher proportion of children in
the placebo group complained of headache. Otherwise,
no differences in symptoms were reported by the
mothers. This corroborates the findings in the studies
cited in a Cochrane review where no differences in reso-
lution of symptoms were found between febrile children
treated with paracetamol or placebo/physical methods
[3]. Similarly, in a review on antipyretic measures for
treatment of fever in malaria, one study reported that
paracetamol alleviated headache whereas no other differ-
ences in the frequency of symptoms were found in the
other studies cited [27].
Vomiting is a major problem in children with malaria
as it interferes with the absorption of anti-malarials. A
study suggested that febrile patients were more likely to
vomit when treated with mefloquine, concluding that
antipyretics might improve the management of malaria
[28]. However, there was no reduction on the incidence
of early vomiting neither with paracetamol nor with
tepid sponging in another study [29]. In the present
study, no differences were found between the groups in
the number of children complaining of vomiting or in
the number having the second dose of chloroquine
repeated.
The authors of the Cochrane review who evaluated
the effect of paracetamol for treatment of fever in chil-
dren concluded that only “inconsistent and weak evi-
dence supports the use of paracetamol to reduce fever
in children” as “the number of reliable studies” are too
few [3]. In the present study, a lower temperature was
Table 1 Description of the children included
Treatment group Paracetamol Placebo
Males/females 91/76 85/86
Age (months)
a 62 (3 - 169) 61 (8 - 190)
Weight (kg)
a 16 (8 - 48) 15 (8 - 43)
Dosage of chloroquine
a,b 27 (20 - 36) 27 (15 - 33)
Parasitaemia on inclusion
c 554 (130 - 1186) 643 (191 - 1132)
a) Median (range in brackets)
b) Mg per kg bodyweight
c) Number of parasites per 200 leucocytes. Median with 25% - 75%
percentiles
Table 2 Temperature of the children measured in the axil
(median with 25% and 75% percentiles in brackets)
Paracetamol group Placebo group
On inclusion 37.6 (36.7 - 39.0) 37.8 (36.7 - 38.9) P = 0.6
Day 0 evening 36.8 (36.2 - 37.6) 37.2 (36.6 - 38.3) P = 0.01
Day 1 morning 36.5 (36.0 - 36.9) 36.4 (36.0 - 36.9) P = 0.8
Day 1 evening 36.1 (35.7 - 36.7) 36.2 (35.8 - 36.7) P = 0.4
Day 2 morning 36.4 (36.0 - 36.7) 36.3 (35.8 - 36.7) P = 0.2
Day 2 evening 35.9 (35.5 - 36.3) 36.0 (35.6 - 36.3) P = 0.3
Day 3 evening 35.9 (35.5 - 36.2) 35.9 (35.4 - 36.1) P = 0.5
A significant difference in temperature was only found in the evening of the
day of inclusion (Mann-Whitney test).
Table 3 Intention to treat analysis of the effect of
treatment with chloroquine 25 mg/kg
Paracetamol-
group*
Placebo-group* OR with confidence
interval**
Day 0 100% (167/167) 100% (171/171)
Day 7 93.3% (152/163) 87.5% (147/168) 0.51 (0.21 - 1.15)
Day 14 84.4% (133/147) 79.6% (131/144) 0.72 (0.40 - 1.28)
Day 21 77.0% (115/126) 75.1% (118/125) 0.87 (0.52 - 1.43)
Day 28 73.6% (108/113) 71.9% (111/116) 0.89 (0.56 - 1.41)
Day 35 72.8% (97/98) 70.5% (102/104) 0.87 (0.55 - 1.37)
The adequate clinical and parasitological response (ACPR) rates in the two
treatment groups (see text):
*) Cumulative percentages of children with ACPR during follow-up. The
number of children with ACPR/total number of children is given in
parenthesis (on day 7 children admitted to hospital on day 0 and children
with early treatment failure are included in the denominator).
**) Cumulative odds ratio of having ACPR in the group treated with placebo
in relation to the paracetamol-group (Mantel-Haenszel weighted odds ratio,
95% confidence interval in brackets).
Table 4 Per protocol analysis of the effect of treatment
with chloroquine 25 mg/kg
Paracetamol-
group*
Placebo-group* OR with confidence
interval**
Day 0 100% (167/167) 100% (171/171)
Day 7 93.3% (152/163) 89.1% (147/165) 0.57 (0.24 - 1.33)
Day 14 84.4% (133/147) 81.0% (131/144) 0.75 (0.41 - 1.35)
Day 21 78.2% (115/124) 76.5% (118/124) 0.85 (0.51 - 1.42)
Day 28 76.8% (108/110) 73.2% (111/116) 0.80 (0.49 - 1.30)
Day 35 76.0% (97/98) 72.5% (102/103) 0.80 (0.49 - 1.29)
The adequate clinical and parasitological response (ACPR) rates in the two
treatment groups (see text):
Excluded due to violation of the protocol: In the paracetamol group 2 and 3
children were treated
outside the study on day 21 and day 28, respectively. In the placebo-group 3
children were admitted to hospital on the day of inclusion and 1 child was
treated outside the study on each of the days 21 and 35.
*) Cumulative percentages of children with ACPR during follow-up. The
number of children with ACPR/total number of children is given in
parenthesis (on day 7, children with early treatment failure are included in the
denominator).
**) Cumulative odds ratio of having ACPR in the group treated with placebo
in relation to the paracetamol-group (Mantel-Haenszel weighted odds ratio,
95% confidence interval in brackets).
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group. However, applying Bonferroni’s correction for
multiple comparisons this result is not statistically
significant.
Many clinicians treat fever with paracetamol to pre-
vent febrile convulsions but there is little evidence
showing that antipyretic treatment reduces the risk of
febrile convulsions [4,30]. However, in accordance with
the improved fever clearance, only two children from
the paracetamol group were admitted to hospital due to
high fever and convulsions on day 0 to day 3 as com-
pared to 6 children from the placebo group, indicating
that paracetamol might play a role in reducing the num-
ber of children suffering from convulsions.
The number of children with parasitaemia on day 3 was
identical in the two treatment groups and no difference in
the number of children with PCR-adjusted treatment fail-
ures was found, but three times as many children in the
paracetamol group were affected when looking on failures
after day 7. However, this higher risk of LCF was out-
weighted by more children in the placebo-group having
ETF or PCR-adjusted treatment failure on day 7 or earlier
indicating that paracetamol diminished the malaria symp-
toms in children and thereby also the need for being seen
by a health professional or being admitted to hospital.
Furthermore, both the cumulative ACPR-rates and the
cumulative PCR-adjusted treatment failure rates on day 28
and day 35 were approximately identical in the two treat-
ment groups. Therefore, the overall outcome of the treat-
ment of malaria in children was not influenced negatively
by adding paracetamol, though the children tended to
experience more treatment failures at a later point when
treated with paracetamol.
Conclusion
In line with previous studies, hardly any differences in
symptoms were found during treatment with paraceta-
mol as compared to treatment with placebo. However,
fewer (2 children vs. 6 children) children were admitted
to hospital due to convulsions and high fever in the para-
cetamol group, though the finding was not statistically
significant. Treatment of children suffering from uncom-
plicated malaria with paracetamol in the doses recom-
mended did not influence the overall cure-rate, however
the clinical beneficial effects are doubtful.
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